Extended Daratumumab-Based Therapy Improves Survival in High-Risk Multiple Myeloma
Kaiser et alThe Lancet Oncology

Five-year follow-up results from the multicenter, externally controlled, phase 2 OPTIMUM/MUKnine trial evaluated induction and extended consolidation therapy using daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed high-risk multiple myeloma. The trial demonstrated sustained improvements in both progression-free survival and overall survival with this risk-stratified extended treatment approach compared with external controls. These long-term outcomes support the clinical adoption of routine molecular diagnostics to facilitate risk identification and tailored management strategies in high-risk patient populations.
Key Takeaways
- Five-year follow-up data from the phase 2 OPTIMUM/MUKnine trial demonstrated sustained improvements in progression-free survival and overall survival using an extended, risk-stratified regimen of daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone compared to external controls.
- The long-term survival benefit supports the implementation of molecular diagnostics to guide risk-stratified, tailored therapy in patients with newly diagnosed high-risk multiple myeloma.
Read the original sourceThe Lancet Oncology
